Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19

• Daniel Clark Files ,

  Contributed equally to this work with: Daniel Clark Files, Frank Tacke

  Affiliation Department of Internal Medicine, Pulmonary, Critical Care, Allergy and Immunology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America

  ⨯
• Frank Tacke ,

  Contributed equally to this work with: Daniel Clark Files, Frank Tacke

  Affiliation Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany

  ⨯
• Alexandra O’Sullivan ,

  ¶‡ AOS, PD, and WGF also contributed equally to this work.

  Affiliation AbbVie Inc., North Chicago, Illinois, United States of America

  ⨯
• Patrick Dorr ,

  ¶‡ AOS, PD, and WGF also contributed equally to this work.

  Affiliation AbbVie Inc., North Chicago, Illinois, United States of America

  ⨯
• William G. Ferguson ,

  ¶‡ AOS, PD, and WGF also contributed equally to this work.

  Affiliation AbbVie Inc., North Chicago, Illinois, United States of America

  ⨯
• William G. Powderly

  * E-mail: wpowderly@wustl.edu

  Affiliation John T. Milliken Department of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine in St Louis, St Louis, Missouri, United States of America

  https://orcid.org/0000-0001-7808-3086

  ⨯